Spero Therapeutics Future Growth
Future criteria checks 1/6
Spero Therapeutics is forecast to grow earnings and revenue by 5.8% and 5% per annum respectively while EPS is expected to grow by 6.2% per annum.
Key information
5.8%
Earnings growth rate
6.2%
EPS growth rate
| Biotechs earnings growth | 24.6% |
| Revenue growth rate | 5.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 16 May 2024 |
Recent future growth updates
Recent updates
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Apr 23Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 12
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jan 02Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
May 18Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Apr 17Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Apr 13We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
Apr 05Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
Oct 03Spero Therapeutics appoints Kamal Hamed MD CMO
Sep 15Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate
Sep 06Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M
Aug 10We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate
Jul 04We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely
Mar 17Sizing Up Spero Therapeutics
Oct 15Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why
Aug 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 56 | -41 | -11 | -10 | 2 |
| 12/31/2025 | 34 | -73 | -52 | -51 | 3 |
| 12/31/2024 | 27 | -69 | N/A | -30 | 3 |
| 3/31/2024 | 111 | 23 | -14 | -14 | N/A |
| 12/31/2023 | 104 | 23 | -33 | -33 | N/A |
| 9/30/2023 | 78 | -2 | 29 | 29 | N/A |
| 6/30/2023 | 54 | -10 | 12 | 12 | N/A |
| 3/31/2023 | 54 | -27 | 8 | 8 | N/A |
| 12/31/2022 | 54 | -46 | -8 | -8 | N/A |
| 9/30/2022 | 9 | -102 | -80 | -80 | N/A |
| 6/30/2022 | 10 | -113 | -84 | -84 | N/A |
| 3/31/2022 | 13 | -103 | -77 | -77 | N/A |
| 12/31/2021 | 18 | -90 | -64 | -64 | N/A |
| 9/30/2021 | 17 | -79 | -53 | -53 | N/A |
| 6/30/2021 | 18 | -76 | -70 | -70 | N/A |
| 3/31/2021 | 15 | -74 | -78 | -78 | N/A |
| 12/31/2020 | 9 | -79 | -86 | -86 | N/A |
| 9/30/2020 | 11 | -85 | -87 | -87 | N/A |
| 6/30/2020 | 12 | -84 | -75 | -75 | N/A |
| 3/31/2020 | 12 | -80 | -63 | -62 | N/A |
| 12/31/2019 | 18 | -61 | -50 | -50 | N/A |
| 9/30/2019 | 16 | -47 | -49 | -46 | N/A |
| 6/30/2019 | 12 | -39 | -45 | -42 | N/A |
| 3/31/2019 | 11 | -36 | -41 | -39 | N/A |
| 12/31/2018 | 4 | -42 | -42 | -40 | N/A |
| 9/30/2018 | 3 | -46 | -39 | -39 | N/A |
| 6/30/2018 | 3 | -47 | -44 | -44 | N/A |
| 3/31/2018 | 3 | -50 | -44 | -44 | N/A |
| 12/31/2017 | 2 | -46 | N/A | -39 | N/A |
| 9/30/2017 | 1 | -40 | N/A | -36 | N/A |
| 6/30/2017 | 1 | -35 | N/A | -32 | N/A |
| 3/31/2017 | 0 | -30 | N/A | -29 | N/A |
| 12/31/2016 | 0 | -30 | N/A | -29 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SPRO's forecast earnings growth (5.8% per year) is above the savings rate (2.4%).
Earnings vs Market: SPRO's earnings (5.8% per year) are forecast to grow slower than the US market (14.8% per year).
High Growth Earnings: SPRO's earnings are forecast to grow, but not significantly.
Revenue vs Market: SPRO's revenue (5% per year) is forecast to grow slower than the US market (8.6% per year).
High Growth Revenue: SPRO's revenue (5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SPRO's Return on Equity is forecast to be high in 3 years time